Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

6.02
+0.28004.88%
Volume:211.16K
Turnover:1.24M
Market Cap:448.57M
PE:-5.92
High:6.03
Open:5.77
Low:5.73
Close:5.74
52wk High:10.00
52wk Low:2.54
Shares:74.51M
Float Shares:57.36M
Volume Ratio:0.60
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0164
EPS(LYR):-1.0214
ROE:-68.67%
ROA:-28.84%
PB:5.59
PE(LYR):-5.89

Loading ...

Corvus Pharmaceuticals : Oppenheimer Cuts Target Price to $15 From $17

THOMSON REUTERS
·
Aug 08

Corvus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Corvus Pharma Q2 EPS $(0.10) Beats $(0.13) Estimate

Benzinga
·
Aug 08

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

GlobeNewswire
·
Aug 08

Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Aug 06

Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Aug 01

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

GlobeNewswire
·
Aug 01

Corvus 'Undervalued' Following Atopic Dermatitis Data From Apogee, Mizuho Securities Says

MT Newswires Live
·
Jul 08

Director and 10% Owner Peter A. Thompson Reports Disposal of Common Shares of Corvus Pharmaceuticals Inc

Reuters
·
Jul 02

Corvus Pharmaceuticals Gets China Nod to Begin Atopic Dermatitis Drug Trial

MT Newswires Live
·
Jun 25

BRIEF-Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval For A Phase 1B/2 Clinical Trial Of Soquelitinib

Reuters
·
Jun 25

Corvus Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 14

Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis

Reuters
·
Jun 04

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating

MT Newswires Live
·
May 20